University Of Mississippi Medical
- Type
- Teaching hospital
- Where
- Jackson, MS
- Medicare CCN
- 250001
- Received
- $1,634,840 in 699 records, 2024 ($477,563 general, $1,157,277 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 107 | $477,563 |
| 2024 | Research payment | 592 | $1,157,277 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 592 | $1,157,277 |
| Grant | 23 | $218,664 |
| Long term medical supply or device loan | 18 | $114,633 |
| Space rental or facility fees (teaching hospital only) | 46 | $92,080 |
| Education | 7 | $34,500 |
| Consulting Fee | 5 | $11,882 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 2 | $4,000 |
| Debt forgiveness | 5 | $1,738 |
| Food and Beverage | 1 | $64 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Merck Sharp & Dohme LLC | $19,131 | Research payment | Cash or cash equivalent | VERQUVO Drug, CARDIOVASCULAR | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2024 |
| 2024-12-31 | Intuitive Surgical, Inc. | $16,850 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $13,422 | Research payment | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2024 |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $10,976 | Research payment | In-kind items and services | ENHERTU Biological, Oncology | Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in | 2024 |
| 2024-12-31 | iRhythm Technologies, Inc. | $9,875 | Research payment | In-kind items and services | ZIO XT Patch Device, Cardiology/Vascular Diseases | STUDY-ARIC-AMP | 2024 |
| 2024-12-31 | Intuitive Surgical, Inc. | $5,000 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Stryker Corporation | $3,505 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $3,505 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $3,436 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Intuitive Surgical, Inc. | $3,400 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Stryker Corporation | $3,061 | Long term medical supply or device loan | In-kind items and services | L11 Device, ENDOSCOPY | 2024 | |
| 2024-12-31 | Stryker Corporation | $828 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Stryker Corporation | $530 | Long term medical supply or device loan | In-kind items and services | Maestro Air Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $477 | Long term medical supply or device loan | In-kind items and services | Connected OR Hub Device, ENDOSCOPY | 2024 | |
| 2024-12-31 | Stryker Corporation | $468 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $438 | Long term medical supply or device loan | In-kind items and services | MISTRAL-AIR Device, PATIENT HANDLING - PH | 2024 | |
| 2024-12-31 | AstraZeneca UK Limited | $347 | Research payment | In-kind items and services | A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Anti | 2024 | |
| 2024-12-31 | Stryker Corporation | $338 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Merck Sharp & Dohme LLC | $170 | Research payment | In-kind items and services | JANUVIA Drug, ENDOCRINOLOGY | A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficac | 2024 |
| 2024-12-31 | ABBVIE INC. | $130 | Research payment | In-kind items and services | M20-621 Ph 3 DLBCL 1L Induction | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $45 | Research payment | Cash or cash equivalent | JANUMET Drug, ENDOCRINOLOGY | A Phase III Multicenter, Double-Blind, Randomized Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy | 2024 |
| 2024-12-31 | Stryker Corporation | $29 | Long term medical supply or device loan | In-kind items and services | ISOFLEX LAL Device, PATIENT HANDLING - PH | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $27 | Research payment | Cash or cash equivalent | JANUVIA Drug, ENDOCRINOLOGY | A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficac | 2024 |
| 2024-12-31 | Stryker Corporation | $23 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | Janssen Research & Development, LLC | $1,160 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $1,375 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $1,375 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $1,054 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-12-23 | Gilead Sciences, Inc. | $19,667 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-12-20 | Novo Nordisk AS | $1,622 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-12-19 | Janssen Research & Development, LLC | $4,105 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-12-17 | Gilead Sciences, Inc. | $93,370 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-12-17 | ARGENX US, INC. | $2,000 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety | 2024 |
| 2024-12-17 | ARGENX US, INC. | $1,680 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety | 2024 |
| 2024-12-17 | ARGENX US, INC. | $900 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety | 2024 |
| 2024-12-12 | ABBVIE INC. | $27,177 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | B19-061 Ph 3 Pediatric Study of venetoclax and chemotherapy | 2024 |
| 2024-12-10 | PROGENICS PHARMACEUTICALS, INC. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PYLARIFY Drug, RADIOPHARMACEUTICAL | 2024 | |
| 2024-12-05 | Fresenius USA Marketing, Inc. | $17,500 | Research payment | Cash or cash equivalent | Safety of Regional Citrate Anticoagulation (SARCA Study) (SARCA) | 2024 | |
| 2024-12-04 | Skeletal Dynamics Inc | $10,000 | Grant | Cash or cash equivalent | Geminus Device, Orthopedic | 2024 | |
| 2024-11-26 | United Therapeutics Corporation | $3,212 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-11-26 | United Therapeutics Corporation | $1,008 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-11-26 | United Therapeutics Corporation | $300 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-11-25 | PFIZER INC. | $3,837 | Research payment | Cash or cash equivalent | SGNDV 001 AN OPEN LABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSU | 2024 | |
| 2024-11-21 | Novocure Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Optune Device, Oncology | 2024 | |
| 2024-11-20 | Novo Nordisk AS | $1,347 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-11-18 | Medical Device Business Services, Inc. | $1,537 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Attune Revision RTKA Population Multi Center Clinical Evaluation of the Attune Revision System in Complex Primary Total | 2024 |
| 2024-11-13 | CSL Behring | $46,351 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-11-13 | Inari Medical, Inc. | $11,850 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THEPEERLESSSTUDY (PEERLESS) | 2024 |
| 2024-11-13 | KLS-Martin L.P. | $2,500 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-11-08 | Genentech, Inc. | $1,322 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | 2024 |
| 2024-11-05 | Genentech USA, Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Vabysmo Drug, Immunology and Ophthalmology | 2024 | |
| 2024-11-04 | Bayer Healthcare Pharmaceuticals Inc. | $307 | Research payment | Cash or cash equivalent | Kerendia Drug, Cardio-renal | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a | 2024 |
| 2024-11-01 | Janssen Research & Development, LLC | $6,247 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-10-31 | Cochlear Americas | $396 | Debt forgiveness | Cash or cash equivalent | COCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution | 2024 | |
| 2024-10-30 | United Therapeutics Corporation | $1,146 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-10-30 | United Therapeutics Corporation | $1,146 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-10-30 | United Therapeutics Corporation | $300 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-10-30 | Abbott Laboratories | $300 | Research payment | Cash or cash equivalent | SJM MASTERS SERIES Device, STRUCTURAL HEART | 15mm Surgical Mechanical Aortic Valve PAS | 2024 |
| 2024-10-29 | PFIZER INC. | $6,450 | Research payment | Cash or cash equivalent | A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG | 2024 | |
| 2024-10-25 | Janssen Research & Development, LLC | $4,702 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2024 |
| 2024-10-16 | CSL Behring | $30,524 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-10-16 | Aurinia Pharma U.S., Inc. | $2,660 | Research payment | Cash or cash equivalent | LUPKYNIS Drug, LUPUS NEPHRITIS | LUPKYNIS Registry Study | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-15 | Novo Nordisk AS | $2,250 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4773 | 2024 |
| 2024-10-09 | United Therapeutics Corporation | $3,288 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-10-07 | Medical Device Business Services, Inc. | $1,035 | Consulting Fee | Cash or cash equivalent | Anspach Helix Device, Power Tools | 2024 | |
| 2024-10-04 | PFIZER INC. | $22,000 | Research payment | Cash or cash equivalent | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGAT | 2024 | |
| 2024-10-03 | Stryker Corporation | $3,710 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NA Device, CRANIOMAXILLOFACIAL | 2024 | |
| 2024-10-02 | PFIZER INC. | $22,833 | Research payment | Cash or cash equivalent | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHER | 2024 | |
| 2024-09-30 | Intuitive Surgical, Inc. | $16,850 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-09-30 | Intuitive Surgical, Inc. | $5,000 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-09-30 | Intuitive Surgical, Inc. | $3,400 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-09-26 | Janssen Research & Development, LLC | $1,684 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-09-25 | United Therapeutics Corporation | $3,725 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-09-25 | United Therapeutics Corporation | $1,100 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-09-24 | Bayer Healthcare Pharmaceuticals Inc. | $1,244 | Research payment | Cash or cash equivalent | Kerendia Drug, Cardio-renal | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a | 2024 |
| 2024-09-20 | Novo Nordisk AS | $1,926 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-09-19 | CSL Behring | $26,820 | Research payment | In-kind items and services | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-09-12 | MED-EL Corporation | $18,180 | Long term medical supply or device loan (2 payments) | In-kind items and services | Mi1250 SYNCHRONY 2 FLEXsoft Device, Cochlear Implant | 2024 | |
| 2024-09-06 | CSL Behring | $18,722 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-09-06 | Bayer Healthcare Pharmaceuticals Inc. | $559 | Research payment | Cash or cash equivalent | Kerendia Drug, Cardio-renal | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a | 2024 |
| 2024-09-05 | AstraZeneca UK Limited | $4,732 | Research payment | Cash or cash equivalent | A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Anti | 2024 | |
| 2024-09-04 | GE HEALTHCARE | $8,007 | Research payment | Cash or cash equivalent | UMMC-GE-278-001-CTA | 2024 | |
| 2024-09-03 | Siemens Medical Solutions USA, Inc. | $1,598 | Grant | In-kind items and services | 2024 | ||
| 2024-09-03 | ABBVIE INC. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | DURYSTA Drug, EYE CARE | 2024 | |
| 2024-08-29 | Stryker Corporation | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-08-28 | United Therapeutics Corporation | $1,500 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-08-28 | United Therapeutics Corporation | $1,283 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-08-27 | Boston Scientific Corporation | $40,354 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | LUX-DX TRENDS | 2024 |
| 2024-08-27 | Inspire Medical Systems, Inc. | $2,275 | Research payment | Cash or cash equivalent | INSPIRE Device, NEUROLOGY | ADH-ADHERE REGISTRY | 2024 |
| 2024-08-27 | Janssen Research & Development, LLC | $2,232 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-08-21 | Novo Nordisk AS | $1,429 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-08-20 | Ivoclar Vivadent, Inc. | $396 | Research payment | In-kind items and services | 2024 | ||
| 2024-08-16 | Medical Device Business Services, Inc. | $491 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Attune Revision RTKA Population Multi Center Clinical Evaluation of the Attune Revision System in Complex Primary Total | 2024 |
| 2024-08-15 | Alexion Pharmaceuticals, Inc. | $10,651 | Research payment | Cash or cash equivalent | KANUMA Biological, Rare Disease | An Observational Disease and Clinical Outcomes Registry of Patients with Lysosomal Acid Lipase (LAL) Deficiency | 2024 |
| 2024-08-14 | Janssen Research & Development, LLC | $14,146 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-08-14 | Alcon Vision LLC | $3,000 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-08-13 | Genentech, Inc. | $1,322 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | 2024 |
| 2024-08-09 | Johnson & Johnson Surgical Vision, Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TECNIS IOL Device, Optics | 2024 | |
| 2024-08-08 | Alexion Pharmaceuticals, Inc. | $17,569 | Research payment | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | A Phase 3, External Placebo Controlled, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab | 2024 |
| 2024-08-08 | United Therapeutics Corporation | $6,815 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-08-08 | Stryker Corporation | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | DURAMATRIX Device, NEURO | 2024 | |
| 2024-08-05 | Medical Device Business Services, Inc. | $1,237 | Consulting Fee | Cash or cash equivalent | Anspach Helix Device, Power Tools | 2024 | |
| 2024-07-31 | PFIZER INC. | $2,500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PHASE 12 STUDY TO EVALUATE PALBOCICLIB IBRANCE IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TO | 2024 |
| 2024-07-31 | United Therapeutics Corporation | $1,558 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-07-31 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PHASE 12 STUDY TO EVALUATE PALBOCICLIB IBRANCE IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TO | 2024 |
| 2024-07-31 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PHASE 12 STUDY TO EVALUATE PALBOCICLIB IBRANCE IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TO | 2024 |
| 2024-07-30 | Regeneron Healthcare Solutions, Inc. | $1,500 | Grant | Cash or cash equivalent | EYLEA Biological, OPHTHALMOLOGY | 2024 | |
| 2024-07-24 | KLS-Martin L.P. | $2,500 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-07-24 | JAZZ PHARMACEUTICALS INC. | $2,000 | Research payment | Cash or cash equivalent | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) | 2024 |
| 2024-07-23 | Siemens Medical Solutions USA, Inc. | $2,500 | Grant | Cash or cash equivalent | EDGE Device, Oncology | 2024 | |
| 2024-07-19 | Galvanize Therapeutics, Inc | $2,571 | Research payment | Cash or cash equivalent | RHEOX Device, PULSED ELECTRIC FIELD | CS006 RHEOX PIVOTAL | 2024 |
| 2024-07-17 | ABBVIE INC. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-07-15 | Medical Device Business Services, Inc. | $7,450 | Consulting Fee | Cash or cash equivalent | Anspach Helix Device, Power Tools | 2024 | |
| 2024-07-15 | Medical Device Business Services, Inc. | $1,050 | Consulting Fee | Cash or cash equivalent | Anspach Helix Device, Power Tools | 2024 | |
| 2024-07-15 | Equashield LLC | $957 | Grant | In-kind items and services | EQUASHIELD Device, Closed System Transfer Device | 2024 | |
| 2024-07-15 | Equashield LLC | $582 | Grant | In-kind items and services | Equashield Device, Closed System Transfer Device | 2024 | |
| 2024-07-15 | Equashield LLC | $232 | Grant | In-kind items and services | Spike Adapter EZ Device, Closed System Transfer Device | 2024 | |
| 2024-07-11 | CSL Behring | $17,880 | Research payment | In-kind items and services | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-07-11 | Alcon Vision LLC | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-07-11 | Stryker Corporation | $1,060 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-07-11 | Stryker Corporation | $1,060 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-07-09 | Janssen Global Services, LLC | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-07-09 | Gilead Sciences, Inc. | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-07-05 | Boston Scientific Corporation | $1,500 | Grant | In-kind items and services | Device, General - Structural Heart_IC | 2024 | |
| 2024-07-01 | Janssen Research & Development, LLC | $1,160 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2024 |
| 2024-06-30 | Intuitive Surgical, Inc. | $16,850 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-06-30 | Intuitive Surgical, Inc. | $5,000 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-06-30 | Intuitive Surgical, Inc. | $3,400 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-06-26 | United Therapeutics Corporation | $4,426 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-06-26 | United Therapeutics Corporation | $2,515 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-06-26 | United Therapeutics Corporation | $1,237 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-06-26 | United Therapeutics Corporation | $1,237 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-06-26 | E.R. Squibb & Sons, L.L.C. | $300 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in | 2024 |
| 2024-06-21 | Novo Nordisk AS | $2,588 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-06-20 | Visby Medical, Inc. | $6,192 | Research payment | Cash or cash equivalent | Visby Medical Sexual Health Click Test Device, Sexual Health Test | Clinical Evaluation of Visby Medical Personal PCR Womens Sexual Health Test for the Detection of Chlamydia trachomatis ( | 2024 |
| 2024-06-20 | Medical Device Business Services, Inc. | $150 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Revision System in Revision Total Knee Arthroplasty | 2024 |
| 2024-06-19 | OrthoPediatrics Corp. | $24,285 | Grant (4 payments) | Cash or cash equivalent | 2024 | ||
| 2024-06-18 | Gilead Sciences, Inc. | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-06-17 | Medical Device Business Services, Inc. | $1,110 | Consulting Fee | Cash or cash equivalent | Anspach Helix Device, Power Tools | 2024 |
The latest 200 records of 699.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Jackson, MS, county Hinds County, MS, state Mississippi; placed by its city name.
| Measure | Place (city or town) Jackson, MS | County Hinds County, MS | State Mississippi |
|---|---|---|---|
| Population B01003 | 146,631 | 218,533 | 2,946,779 |
| Population, 2020 census P1 | 153,701 | 227,742 | 2,961,279 |
| Median age B01002 | 34.5 | 36.9 | 38.6 |
| Under 18 B01001 | 23.9% | 23.5% | 23.3% |
| 65 and over B01001 | 15.0% | 16.3% | 17.2% |
| Households B11001 | 61,415 | 89,578 | 1,145,431 |
| Foreign born B05002 | 1.6% | 2.0% | 2.4% |
| Median household income B19013 | $42,071 | $49,402 | $56,447 |
| Median family income B19113 | $52,810 | $64,969 | $73,163 |
| Per capita income B19301 | $26,811 | $29,530 | $31,549 |
| Poverty rate B17001 | 27.9% | 22.7% | 18.9% |
| Unemployment rate B23025 | 9.3% | 7.5% | 5.8% |
| Civilian labor force B23025 | 69,393 | 102,828 | 1,332,121 |
| Mean commute (minutes) B08013 | 19.9 | 22.3 | 25.6 |
| Bachelor's degree or higher B15003 | 28.8% | 31.2% | 25.1% |
| Housing units B25001 | 74,871 | 106,340 | 1,341,114 |
| Owner-occupied B25003 | 48.6% | 58.3% | 70.0% |
| Renters B25003 | 51.4% | 41.7% | 30.0% |
| Median home value B25077 | $111,700 | $159,900 | $169,800 |
| Median gross rent B25064 | $1,055 | $1,061 | $954 |
| White, not Hispanic B03002 | 13.3% | 22.9% | 55.2% |
| Black B03002 | 81.7% | 71.7% | 36.3% |
| Hispanic or Latino B03002 | 2.4% | 2.1% | 3.7% |
| Asian B03002 | 0.3% | 0.8% | 1.0% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.4% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Jackson, MS.
Comments